14.21

1.65% 0.23

Neogenomics Inc (NEO)

Overview News Price History Option Chain Financials Why NEO Down? Discussions Forecast Stock Split

Neogenomics Inc stock is traded at $14.21, with a volume of 885.14K. It is up +1.65% in the last 24 hours and down -19.03% over the past month. NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Previous Close:

$13.98

Open:

$14.12

24h Volume:

885.14K

Relative Volume:

1.16

Market Cap:

$1.82B

Revenue:

$628.25M

Net Income/Loss:

$-78.55M

P/E Ratio:

-22.92

EPS:

-0.62

Net Cash Flow:

$-29.73M

1W Performance:

-3.79%

1M Performance:

-19.03%

6M Performance:

-8.32%

1Y Performance:

-8.09%

1-Day Range:

$14.01

$14.57

1-Week Range:

$12.12

$16.18

52-Week Range:

$12.12

$19.11

Neogenomics Inc Stock (NEO) Company Profile

Name

Neogenomics Inc

Sector

Healthcare (1174)

Industry

Diagnostics & Research (58)

Phone

(239) 768-0600

Address

9490 NEOGENOMICS WAY, FORT MYERS, FL

Employee

2,100

Twitter

@NeoGenomics

Next Earnings Date

2024-11-05

Latest SEC Filings

NEO's Discussions on Twitter

Compare NEO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NEO Neogenomics Inc	14.21	1.82B	628.25M	-78.55M	-29.73M	-0.62
TMO Thermo Fisher Scientific Inc	559.65	214.07B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	238.36	172.16B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	147.36	42.09B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	197.36	35.82B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	419.26	34.33B	3.84B	866.24M	792.60M	10.37

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Downgrade	The Benchmark Company	Buy → Hold
Dec-10-24	Initiated	Jefferies	Buy
May-01-24	Resumed	Craig Hallum	Buy
Dec-29-23	Reiterated	BTIG Research	Buy
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy
Feb-01-23	Upgrade	Needham	Hold → Buy
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight
Jan-18-22	Resumed	Stephens	Overweight
Dec-16-21	Initiated	Cowen	Outperform
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-03-21	Initiated	Goldman	Buy
Feb-25-21	Resumed	Needham	Buy
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-28-21	Initiated	Truist	Buy
Dec-11-20	Resumed	BTIG Research	Buy
Oct-28-20	Reiterated	Needham	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Aug-28-20	Initiated	Guggenheim	Buy
Jul-29-20	Reiterated	Needham	Buy
Jun-25-20	Initiated	BofA/Merrill	Buy
Apr-21-20	Resumed	Stephens	Overweight
Mar-02-20	Resumed	Craig Hallum	Buy
Feb-28-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Jan-23-20	Downgrade	First Analysis Sec	Strong Buy → Outperform
Oct-30-19	Reiterated	Needham	Buy
May-01-19	Reiterated	Needham	Buy
Mar-29-19	Reiterated	Needham	Buy
Jan-03-19	Initiated	Needham	Buy
Oct-24-18	Upgrade	First Analysis Sec	Outperform → Strong Buy
Aug-21-18	Initiated	Leerink Partners	Outperform
May-02-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-11-17	Downgrade	BTIG Research	Buy → Neutral
Aug-24-17	Initiated	Gabelli & Co	Buy
Dec-15-16	Initiated	Cantor Fitzgerald	Overweight

View All

Neogenomics Inc Stock (NEO) Latest News

Jan 19, 2025

Benchmark retains Hold on Neogenomics stock, raises 2025 revenue forecast By Investing.com - Investing.com Canada

Jan 16, 2025

Neogenomics stock sees solid support from Needham on updated guidance and expansion plans - Investing.com Canada

Jan 16, 2025

Jan 15, 2025

NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance - Yahoo! Voices

Jan 15, 2025

Medtech Surges, Reversing CEO-Tied Selloff, On Long-Term Guide - Investor's Business Daily

Jan 15, 2025

NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan

Jan 15, 2025

5 Analysts Assess NeoGenomics: What You Need To Know - Benzinga

Jan 15, 2025

NeoGenomics (NASDAQ:NEO) Shares Gap UpStill a Buy? - MarketBeat

Jan 15, 2025

NeoGenomics rises on upbeat sales outlook for 2025 - MSN

Jan 15, 2025

NeoGenomics stock rises on upbeat 2025 financial outlook By Investing.com - Investing.com Nigeria

Jan 15, 2025

NeoGenomics stock rises on upbeat 2025 financial outlook - Investing.com

Jan 15, 2025

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga

Jan 15, 2025

NeoGenomics Announces Executive Bonuses and Revenue Growth - TipRanks

Jan 15, 2025

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - The Bakersfield Californian

Jan 15, 2025

NeoGenomics Projects Strong Growth: 43-51% EBITDA Jump, $735M+ Revenue Target for 2025 - StockTitan

Jan 15, 2025

Adaptive, NeoGenomics partner to expand access to disease monitoring - MSN

Jan 15, 2025

Jan 14, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand - GlobeNewswire

Jan 14, 2025

Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha

Jan 14, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - The Manila Times

Jan 14, 2025

Adaptive Biotech Partners with NeoGenomics to Transform Blood Cancer Testing with clonoSEQ - StockTitan

Jan 14, 2025

What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash - Simply Wall St

Jan 14, 2025

NeoGenomics (NASDAQ:NEO) Sets New 52-Week LowWhat's Next? - MarketBeat

Jan 14, 2025